posted on 2017-11-21, 00:00authored byDong-Oh Yoon, Xiaodi Zhao, Dohyun Son, Jung Tae Han, Jaesook Yun, Dongyun Shin, Hyun-Ju Park
G-protein coupled
receptor 40 (GPR40) has been considered to be
an attractive drug target for the treatment of type 2 diabetes because
of its role in free fatty acids-mediated enhancement of glucose-stimulated
insulin secretion (GSIS) from pancreatic β-cells. A series of
indole-5-propanoic acid compounds were synthesized, and their GPR40
agonistic activities were evaluated by nuclear factor of activated
T-cells reporter assay and GSIS assay in the MIN-6 insulinoma cells.
Three compounds, 8h (EC50 = 58.6 nM), 8i (EC50 = 37.8 nM), and 8o (EC50 = 9.4 nM), were identified as potent GPR40 agonists with
good GSIS effects.